Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK
View through CrossRef
Enfortumab vedotin (Padvec™; Astellas Pharma and Pfizer) in combination with pembrolizumab (Keytruda®; Merck & Co/Merck Sharp & Dohme) has been approved a a first-line treatment by the National Institute for Health and Care Excellence (NICE) for prescription for unresectable or metastatic urothelial cancer in the United Kingdom (UK).
Title: NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UK
Description:
Enfortumab vedotin (Padvec™; Astellas Pharma and Pfizer) in combination with pembrolizumab (Keytruda®; Merck & Co/Merck Sharp & Dohme) has been approved a a first-line treatment by the National Institute for Health and Care Excellence (NICE) for prescription for unresectable or metastatic urothelial cancer in the United Kingdom (UK).
Related Results
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract
Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL
Abstract
Abstract 3699
Background:
A defining feature of HL is CD30 expression by Reed-Sternberg cells. Brentuxim...
THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
Abstract
Disclosure: M. Hussein: None.
Introduction: Immunotherapy has transformed the treatment landscape of cancer therapy and has created promising...
YAP1 and downstream gene alterations in metastatic breast cancer.
YAP1 and downstream gene alterations in metastatic breast cancer.
e13121
Background:
Metastatic breast cancer remains a major clinical challenge, characterized by poor prognosis and limited therapeuti...
Spanish Breast Cancer Research Group (GEICAM)
Spanish Breast Cancer Research Group (GEICAM)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Spanish Breast Cancer Research Group (GEICAM). Clinical trials...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.
e12658 Background: Triple-negative breast cancer (TNBC) has limited treatment options. KEYNOTE 522 led to the approval of neoadjuvant (NT) Pembrolizumab in July 2021 changing the ...
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia.
e19385 Background: Pembrolizumab has dramatically improved the survival of patients with non-small cell lung cancer (NSCLC) and is considered the standard of care for first line t...